Core Viewpoint - AEON Biopharma, Inc. is facing non-compliance with NYSE American listing standards due to a stockholders' deficit of $32.1 million and reported losses in two of the last three fiscal years [1][2] Group 1: Compliance and Regulatory Actions - AEON must submit a plan to regain compliance by March 5, 2025, with a deadline to meet listing standards by August 3, 2026 [2] - If the plan is accepted, AEON will undergo periodic reviews; failure to comply may lead to delisting proceedings [2] - The notice does not immediately affect the trading status of AEON's common stock, which will continue to trade under the symbol "AEON" with a ".BC" designation indicating non-compliance [3] Group 2: Company Overview - AEON is a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex, ABP-450, for medical conditions, particularly in the neurosciences market [5] - ABP-450 is the same product marketed for cosmetic use as Jeuveau and is approved as a biosimilar in Mexico and India [5] - The company has exclusive rights for therapeutic indications of ABP-450 in several regions, including the U.S., Canada, and the EU [5]
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards